Search
Arvinas Inc
ARVNAdd to Watchlist
8.390USD
+0.190+2.32%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
594.01MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.32%
5 Days
+4.88%
1 Month
+8.40%
6 Months
-26.85%
Year to Date
-29.26%
1 Year
+5.53%
Key Figures
8.295Open
8.670High
643.67KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.91%Turnover Ratio
8.200Prev. Close
8.155Low
4.07MTurnover
LossP/E Static
1.05P/B
0.00%Div Yield TTM
-26.85%ROA
14.51052wk High
0.91Volume Ratio
-198.90MNet Profit
70.80MShares
-3.1831EPS TTM
1.76Beta
-42.28%ROE
6.05552wk Low
6.28%Amplitude
100.00%Gross Margin
594.01MMarket Cap
1.82Reward/Risk
3.27%Risk Rate
TradingKey Stock Score of Arvinas Inc
Currency: USD Updated: 2026-07-02Key Insights
Arvinas Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 111 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.40.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Arvinas Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Arvinas Inc Highlights
StrengthsRisks
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 234.52% year-on-year.
Overvalued
The company’s latest PE is -2.64, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 53.93M shares, decreasing 45.68% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 326.55K shares of this stock.
Analyst Rating
Based on
18
analysts
Buy
Current Rating
15.400
Target Price
+87.80%
Upside Space
Arvinas Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Arvinas Inc Info
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Ticker SymbolARVN
CompanyArvinas Inc
CEODr. John G. Houston, Ph.D.
Websitehttps://www.arvinas.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Arvinas Inc (ARVN)?
The current price of Arvinas Inc (ARVN) is 8.39.
What is the symbol of Arvinas Inc?
The ticker symbol of Arvinas Inc is ARVN.
What is the 52-week high of Arvinas Inc?
The 52-week high of Arvinas Inc is 14.51.
What is the 52-week low of Arvinas Inc?
The 52-week low of Arvinas Inc is 6.05.
What is the market capitalization of Arvinas Inc?
The market capitalization of Arvinas Inc is 594.01M.
Is Arvinas Inc (ARVN) currently rated as Buy, Hold, or Sell?
According to analysts, Arvinas Inc (ARVN) has an overall rating of Buy, with a price target of 15.40.
What is the Earnings Per Share (EPS TTM) of Arvinas Inc (ARVN)?
The Earnings Per Share (EPS TTM) of Arvinas Inc (ARVN) is -1.14.